A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection

Exclusion Criteria

• •1. Participants known to be allergic to the investigational medicinal product or those suffering from severe allergic conditions；
• •2. Suspect or diagnosed as tetanus;
• •3. Previously diagnosed as Immunoglobulin A (IgA) deficiency with anti-IgA antibodies；
• •4. Prior vaccination history of ≥ 3 doses of tetanus toxoid or tetanus toxoid- containing vaccine;
• •5. Females who are pregnant or with pregnancy test positive.